The aim of the STEP7 project is the development and clinical evaluation of the first-in-class 5-HT7 receptor agonist as an analgesic drug in neuropathy therapy, which is a major clinical problem and a huge socio-economic burden. The project will be implemented by a scientific consortium composed of the pharmaceutical company Celon Pharma S.A. and the Institute of Pharmacology named after J. Maja PAS. The project is based on the results obtained for AGH-194 (patent No EP16461543). In preliminary studies in in vitro models, this molecule showed very promising properties: high activity against 5-HT7 receptor, selectivity, good water solubility. In vivo models have shown oral bioavailability in mice and strong and rapid blood penetration into the brain and strong analgesic effects of AGH-194. The project will be implemented for 49 months in 9 phases. The first 8 phases will cover industrial studies, i.e. physicochemical characterisation of compounds, ADMET and in vitro and in vivo biological activity, including performance testing and exclusion of non-specific mechanisms of action. Based on the results of these experiments, a decision will be made on the further development of AGH-194 or on the selection of a new, better-compliant molecule from the concurrently tested so-called back-up compounds. In further stages, formulae will be developed for the leading association, the increase in synthesis and the receipt of compounds in the GMP standard and toxicological studies will be developed in accordance with Article 25 of the EC Regulation No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ Urz. EU L 187/1 of 26.06.2014));